Radioimmunotherapy with astatine-211 using chimeric monoclonal antibody U36 in head and neck squamous cell carcinomaJUNPING CHENG; EKBERG, Tomas; ENGSTRÖM, Mats et al.The Laryngoscope. 2007, Vol 117, Num 6, pp 1013-1018, issn 0023-852X, 6 p.Article

Evaluation of Limited blood sampling in a preceding ^99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of ¹⁸⁶Re-cMAb U36 radioimmunotherapyCOLNOT, David R; WILHELM, Abraham J; CLOOS, Jacqueline et al.The Journal of nuclear medicine (1978). 2001, Vol 42, Num 9, pp 1364-1367, issn 0161-5505Article

Targeting of a head and neck squamous cell carcinoma xenograft model using the chimeric monoclonal antibody U36 radioiodinated with a closo-dodecaborate-containing linkerJUNPING CHENG; PERSSON, Mikael; TOLMACHEV, Vladimir et al.Acta oto-laryngologica. 2004, Vol 124, Num 9, pp 1078-1085, issn 0001-6489, 8 p.Article

Sequence variation in the monoclonal-antibody-U36-defined CD44v6 epitopeVAN HAL, N. L. W; VAN DONGEN, G. A. M. S; TEN BRINK, C. B. M et al.Cancer immunology and immunotherapy. 1997, Vol 45, Num 2, pp 88-92, issn 0340-7004Article

Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancerDE BREE, R; ROOS, J. C; QUAK, J. J et al.Clinical cancer research. 1995, Vol 1, Num 6, pp 591-598, issn 1078-0432Article